Top Industry Leaders in the Pharmacogenomics Market
Illumina (ILMN) Acquired GRAIL, a leader in cancer detection through circulating tumor DNA (ctDNA), for $8 billion. This strengthens Illumina's position in personalized medicine and early cancer detection.
Invitae (NVTA) Acquired Counsyl, a company specializing in prenatal and genetic carrier testing, for $1.2 billion. This expands Invitae's reach in reproductive health and positions them as a key player in personalized medicine.
Numares Health Secured FDA clearance for their AXINON® LDL-p Test System, the first commercially available NMR test for measuring LDL-p (particle number), a more precise indicator of cardiovascular risk than traditional LDL-C.
Biogen (BIIB) Announced positive Phase 2b data for aducanumab, an Alzheimer's disease treatment targeting beta-amyloid plaques. This reignites hope for a potential breakthrough in this challenging disease.
Pacific Biosciences (PACB) Unveiled their Revio™ long-read sequencing technology, offering unprecedented accuracy and resolution for whole-genome sequencing. This has significant implications for pharmacogenomics research and personalized medicine.
Guardant Health (GH) Developed the Lunar-Dx test, which combines liquid biopsy and tissue testing to provide a more comprehensive picture of tumor mutations and potential treatment options. This personalized approach holds promise for improved cancer care.
List of Pharmacogenomics Key Companies in the Market
-
Myriad Genetics, Inc. (U.S.)
-
23andMe, Inc. (U.S.)
-
Pathway Genomics (U.S.)
-
GeneTech (U.S.)
-
Future Science Group (U.S.)
-
Teva Pharmaceutical Industries Ltd. (Israel)
-
Assurex Health, Inc. (U.S.)
-
Bristol-Myers Squibb Company
-
Hoffmann-La Roche Ltd.
-
Merck & Co., Inc.
-
Johnson & Johnson
-
Abbott Laboratories, Inc.